SUMMARY: Vertebral fracture assessment (VFA) is a convenient tool for the diagnosis of vertebral fracture in RA. Optimal control of inflammation may be an effective means to protect against vertebral fractures. INTRODUCTION: The aim of this case-control study was to assess the prevalence of vertebral fractures (VFs) in patients with RA using VFA technology. METHODS: Consecutive women (N = 101, 56.1 ± 14.2 years) with RA (mean disease duration, 14.9 ± 10 years) were recruited in the study. Clinical and biological statuses and treatments including glucocorticoids were assessed. Controls (N = 303), randomly selected from the general population, were individually matched to each case for age. RESULTS: The prevalences of osteoporosis were 55.4% and 10.5% in patients and controls, respectively. Among the subjects, 21.7% and 4.2% had a vertebral fracture in the RA and control groups, respectively. Compared with controls, patients with RA had an increased risk of VFs: odds ratio (OR) (CI 95%) adjusted on body mass index was 6.5 (3.1, 13.9). In a multiple logistic regression analysis, VFs were independently associated with presence of non-vertebral fractures (OR = 9.2 [2.5-33.5]), presence of a fall in the previous year (OR = 4.6 [1.2-18.3]), current use of disease-modifying anti-rheumatic drugs (DMARDs) (OR = 0.05 [0.004, 0.51]) and current use of steroids (OR = 0.17 [0.04, 0.67]). CONCLUSION: Rheumatoid arthritis is a risk factor of VF (OR = 6.5). VFA is a convenient tool for this diagnosis. Presence of VF is inversely related to the use of DMARD and glucocorticoids, enhancing the hypothesis that an appropriate control of the disease may be a protective factor against bone fragility.
SUMMARY:Vertebral fracture assessment (VFA) is a convenient tool for the diagnosis of vertebral fracture in RA. Optimal control of inflammation may be an effective means to protect against vertebral fractures. INTRODUCTION: The aim of this case-control study was to assess the prevalence of vertebral fractures (VFs) in patients with RA using VFA technology. METHODS: Consecutive women (N = 101, 56.1 ± 14.2 years) with RA (mean disease duration, 14.9 ± 10 years) were recruited in the study. Clinical and biological statuses and treatments including glucocorticoids were assessed. Controls (N = 303), randomly selected from the general population, were individually matched to each case for age. RESULTS: The prevalences of osteoporosis were 55.4% and 10.5% in patients and controls, respectively. Among the subjects, 21.7% and 4.2% had a vertebral fracture in the RA and control groups, respectively. Compared with controls, patients with RA had an increased risk of VFs: odds ratio (OR) (CI 95%) adjusted on body mass index was 6.5 (3.1, 13.9). In a multiple logistic regression analysis, VFs were independently associated with presence of non-vertebral fractures (OR = 9.2 [2.5-33.5]), presence of a fall in the previous year (OR = 4.6 [1.2-18.3]), current use of disease-modifying anti-rheumatic drugs (DMARDs) (OR = 0.05 [0.004, 0.51]) and current use of steroids (OR = 0.17 [0.04, 0.67]). CONCLUSION:Rheumatoid arthritis is a risk factor of VF (OR = 6.5). VFA is a convenient tool for this diagnosis. Presence of VF is inversely related to the use of DMARD and glucocorticoids, enhancing the hypothesis that an appropriate control of the disease may be a protective factor against bone fragility.
Authors: Jeffrey R Curtis; Andrew O Westfall; Jeroan Allison; Angela Becker; Mary Elkins Melton; Allison Freeman; Catarina I Kiefe; Marilyn MacArthur; Theresa Ockershausen; Emily Stewart; Norm Weissman; Kenneth G Saag Journal: Arch Intern Med Date: 2007-03-26
Authors: R N de Nijs; J W Jacobs; J W Bijlsma; W F Lems; R F Laan; H H Houben; E J ter Borg; A M Huisman; G A Bruyn; P L van Oijen; A A Westgeest; A Algra; D M Hofman Journal: Rheumatology (Oxford) Date: 2001-12 Impact factor: 7.580
Authors: Georg Schett; Stefan Kiechl; Siegfried Weger; Angelo Pederiva; Agnes Mayr; Manuele Petrangeli; Friedrich Oberhollenzer; Rolando Lorenzini; Kurt Redlich; Roland Axmann; Jochen Zwerina; Johann Willeit Journal: Arch Intern Med Date: 2006 Dec 11-25
Authors: Ragnhild E Orstavik; Glenn Haugeberg; Till Uhlig; Petter Mowinckel; Jan A Falch; Johan I Halse; Tore K Kvien Journal: Osteoporos Int Date: 2004-06-12 Impact factor: 4.507
Authors: Gulsen Ozen; Diane L Kamen; Ted R Mikuls; Bryant R England; Frederick Wolfe; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2018-03-11 Impact factor: 4.794
Authors: María L Brance; Lucas R Brun; Susana Lioi; Ariel Sánchez; Marcelo Abdala; Beatriz Oliveri Journal: Rheumatol Int Date: 2014-07-01 Impact factor: 2.631